UK Medicines Information
Certolizumab pegol for treating moderate to severe plaque psoriasis – guidance (TA574)
Information type:
Guidance
Source:
National Institute for Health and Care Excellence
Specialities:
Skin disorders
Summary
Certolizumab pegol is recommended as an option for treating severe plaque psoriasis in adults (PASI 10 or more and DLQI >10) only if disease hasn't responded to other systemic treatments, or these options are contraindicated or not tolerated and lowest maintenance dosage is used.
UKMi comment
Related links: